# Zhejiang Silicon Paradise Asset Management Group

> Zhejiang Silicon Paradise Asset Management Group is a VC fund backing Medical and Health Care. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Hangzhou, China
- Total investments: 6
- Last investment: Jul 2024
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/天堂硅谷股权投资管理有限公司
- Website: http://en.ttgg.com.cn/

Zhejiang Silicon Paradise Asset Management Group is a private equity fund manager that focuses on equity investment in the smart technology, advanced manufacturing, and healthcare industries.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 33% |
| Health Care | 2 | 33% |
| Medical Device | 2 | 33% |
| Biopharma | 1 | 17% |
| Enterprise | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Series B | 2 | 33% |
| Seed | 1 | 17% |
| Series D | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 4 | 67% |
| United States | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xinzeyuan Medical | Xinzeyuan Medical is a manufacturer of key precision components and medical endoscope consumables. | $14.3M | Series B | Jul 08, 2024 |  |
| MetaLenX | MetaLenX is a technology-based enterprise focusing on the design, manufacture and application of superlenses. | $13.7M | Series A | Oct 10, 2023 |  |
| Blue Wave | Blue Wave is a producer of Industrial IoT and Internet of Vehicles chips. | $13.7M | Seed | Sep 12, 2023 |  |
| remd | remd is a forward-thinking developer of irreversible electroporation technology, focusing on the research, development, production, and sale of the third type of medical equipment for tumour treatment, with high-frequency irreversible electroporation as its core technology. | $14.6M | Series A | Feb 17, 2023 |  |
| Denovo Biopharma | Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stageclinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology. | $42.5M | Series D | Dec 10, 2020 |  |
| ZStack | ZStack Cloud Platform has served more than 1,000 enterprise users and established ecological and channel partnerships with more than 200 cloud vendors, covering government, finance, education, internet, energy, manufacturing and many other industries. | $33.2M | Series B | Aug 19, 2020 |  |

6 of 6 investments shown.

## Co-investors
- [Zhejiang Paradise](https://shizune.co/investors/profile/zhejiang-paradise-silicon-valley-asset-management-group) — VC Fund, 5 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- [Alibaba Group](https://shizune.co/investors/profile/alibaba) — VC Fund, 1 deal together
- [BOCOM International](https://shizune.co/investors/profile/bocom-international) — VC Fund, 1 deal together
- [Chengdu High-tech Ceyuan Capital](https://shizune.co/investors/profile/chengdu-high-tech-ceyuan-capital) — VC Fund, 1 deal together
- [China Internet Investment Fund](https://shizune.co/investors/profile/china-internet-investment-fund) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Zhejiang Silicon Paradise Asset Management Group invest in?

Zhejiang Silicon Paradise Asset Management Group invests primarily in Medical, Health Care and Medical Device startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Zhejiang Silicon Paradise Asset Management Group last invest?

The most recent investment recorded for Zhejiang Silicon Paradise Asset Management Group closed in Jul 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co